Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zetia approved in Japan

April 19, 2007

New Zealand regulator approves phase I/IIa study of DiabeCell

April 19, 2007

Phase III confirmatory study of DX-88 for HAE begins treatment

April 19, 2007

Reclast approved for Paget's disease

April 18, 2007

Once-weekly formulation of risedronate sodium approved in Japan

April 18, 2007

Further analysis of CRD5 phase I/II data

April 18, 2007

Promacta studied in patients previously treated for chronic ITP

April 17, 2007

Positive topline phase II results for DX-88 in hereditary angioedema

April 17, 2007

Concerns over link between Xenical and gallstones

April 16, 2007

Novel dual PARPalpha/gamma agonists as potential antidiabetics

April 16, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...